No content results match your keyword.
Content
You have successfully logged out.
Not registered yet?
No content results match your keyword.
Content
No product results match your keyword.
Products
Nutrition therapy
In everyday life, we don’t consider that nutrition could ever be a problem, but malnutrition, specifically undernourishment, is underestimated with more than 3 million people
in the UK being at risk6.
Malnutrition is defined as a state of nutritional imbalance of energy, protein, and nutrients that can lead to adverse effects on health. Undernourishment is seen as a combination of poor appetite and unintended weight loss over a period of time.
Malnutrition persists as a multifaceted challenge across the nation and has huge ramifications on quality of life in the community, and clinical outcomes in healthcare settings.
By clicking 'Confirm” you declare that you are a health care professional. If you are a member of the public, we will redirect you to the pages dedicated to you.
Confirm Yes, I am a health care professional. Cancel No, I am not a health care professional.
Identifying undernourished patients is crucial. In cases of malnutrition, healthcare professionals will choose the most appropriate treatment and care pathway for their patient. This could include nutritional supplements, enteral nutrition and/or parenteral nutrition.
Healthcare professionals should consider parenteral nutrition in people who are malnourished or at risk of malnutrition, and who meet either of the following criteria:
At B. Braun, we pride ourselves on collaboration with healthcare professionals to provide nutrition solutions that improve patients' outcomes for undernourished patients requiring parenteral nutrition.
Screening patients using national guidelines such as MUST (Malnutrition Universal Screening Tool) is the first step in identifying patients requiring nutritional intervention. MUST is based on the BMI, current weight loss and acute disease effect. The tool can be used by healthcare professionals in the assessment to support identification for clinical action.
The MUST is recommended by BAPEN, ESPEN and the ESPEN guidelines for oncology as a screening tool for adult patients.
XX-WEBMN-05-24
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to B. Braun Medical Ltd (tel: 0800 298 0299)
XX-WEBNT-05-24
References
Register or login below to access your personalised account, with applications and content tailored specifically to you and your speciality.
